OCTO-TELEMATICS
The social context of pervasive technologies in everyday life and a more complex working environment is driving the Digital Transformation of the global Insurance industry attracting new stakeholders to enter in the traditional value chain.
In this White Paper , which contains quotes from Gartner’s Predicts 2020: Digital Challenges Slow Down Insurance Industry Transformation’ report (December 2019) , we would like to explain how Digital Driver Essentials, OCTO’s range of telematic experiences allows our stakeholders, businesses and consumers to have smart, intuitive and technologically-advanced solutions, capable of giving immediate advantages in terms of loyalty, profiling, risk analysis and a positive influence on driving behaviour, assisting drivers in an accident and making their experience with the insurance company more pleasant.
The example of OCTO’s proposed path to step-by-step telematics adoption is the “DIGITAL DRIVER ESSENTIALS ” product, a complete and modular offering of digital solutions that leverages the potential of mobile technologies to facilitate the introduction of telematics and to increase customer engagement throughout the policy lifecycle.
This solution can benefit CIOs, Risk, Claim and Marketing managers looking to accelerate the embrace of a new market approach. Leveraging the app as an interaction channel, insurance companies can build a new customer experience, reinforcing the relationship through continuous engagement.
The product addresses the B2B2C model and provides different web profiles and platform interfaces to facilitate these operations.
For the policyholder it comes in two different configurations:
- Digital Driver Smartphone Edition: a comprehensive “telematic experience” in the driver’s hands. The end user is encouraged to adopt safer driving behaviours thanks to the implementation of the Driver Coaching functions (the detection of events that distract the user from driving) and the DriveAbility® scoring (the most accurate algorithm for assessing the user’s driving style).
- Digital Driver SmartTag Edition: based on the use of the smartphone associated with the OCTO SmartTag installed on the windshield which allows a wider range of use and additional services. This helps to improve safety in the event of an accident. The SmartTag edition enriches the Smartphone edition with assistance to the user in the event of an accident. The end user is identified within their vehicle and the assistance room is able to provide them with help and support immediately. In addition, once the urgency is over, the solution will allow the customer to manage the event more effectively with their insurance company.
OCTO has tested the reliability of its smart tag associated with the OCTO Digital Driver application, a solution capable of automatically detecting and reporting over 95% of accidents occurring at speeds in excess of 5 miles per hour. At the same time, false alarms are incredibly low at less than 1% of customers every year.
Benefits for Claim Managers and Fleet managers
For seamless and touchless claims handling, OCTO can reduce the process from months to days, offering significant savings from process improvements and mitigating further loss such as fraud or the downtime of fleet vehicles. Claim managers and fleet managers can benefit from instant FNOL (first notice of loss) for proactively improving the loss ratio or managing the fleet, as well as receiving a detailed dossier of events. This dossier can help reduce claim adjustments and avoid accident investigations for the insurer, while helping fleet managers identify areas for improvement in driver training. In parallel, the user experience is also greatly enhanced from near real-time support at the time of need, such as emergency services, breakdown assistance, or the reallocation of the fleet, to a quicker settlement of claims.
Effectiveness OCTO Crash
At OCTO, this all begins with the most advanced crash analytics, built from Machine Learning algorithms using the most comprehensive claims event database in the world. With half a million events fully analyzed as genuine claims and processed by the insurance industry, it is also the most mature and proven telematics-based claims solution available today.
Available as part of the Digital Driver SmartTag Edition, OCTO’s expertise and effective crash and claims service is now part of a low friction, easy to adopt solution. The benefits of crash detection can be enabled within minutes, quickly enhancing the user experience. Process improvements to claim handling as part of the business operations can also be introduced with the support of OCTO to speed up the period of return on investment (ROI).
ABOUT OCTO
Founded in 2002, OCTO is a leading provider of telematic services and advanced data analytics for the insurance sector, and increasingly one of the leading companies offering solutions for Fleet Telematics and Smart Mobility. With OCTO’s unique propositions already established in the field of Insurtech and Smart Mobility, OCTO continues to expand in new sectors and international markets. In the context of an increasingly connected world, OCTO’s advanced analytics and its set of IoT Big Data, generates actionable analytics giving life to a new era of Smart Telematics. Today it has over 6 million connected users and the largest database of vehicle telematics data in the world, with over 267 billion miles of driving data collected and 480,000 claims and insurance events analysed. It also manages over 400,000 vehicle rentals per month.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201014005433/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
